Log inA patent has been filed for using hyaluronic acid nanogel to develop a novel COVID-19 vaccine
February. 22, 2022
A patent has been filed for using hyaluronic acid nanogel to develop a novel COVID-19 vaccine
Our hyaluronic acid nanogel (HA nanogel) technology
- Uses biologically derived materials as the delivery vehicle to minimize adverse reactions to the vaccines
- Paving the way for the development of vaccines that can withstand transportation at room-temperature
- Increased titers of virus-neutralizing antibodies, sustained vaccine efficacy for more than one year, and induction of immune memory through experiments on mice vaccinated twice
Application Overview
Recently, Asahi Kasei has developed an innovative COVID-19 vaccine technology based on HA nanogel, in collaboration with Shimane University (Prof. Takeshi Urano), Kyoto University (Prof. Kazunari Akiyoshi), Mie University (Prof. Hiroshi Shiku), and Nagasaki University (Prof. Kouichi Morita). We completed the patent application process on December 16, 2021 (Japanese Patent Application No. 2021-204470).
Our technology could be used to develop vaccines that can be safely administered to children because HA nanogel is a biologically derived material that does not contain polyethylene glycol and can effectively deliver antigens to immune tissues. In addition, the vaccines may not require to be stored in a cold chain (in other words, it can be delivered at room temperature) because HA nanogel remains fully effective even when lyophilized.
Please contact us if you have any questions regarding the application.
New Product Development Office, Functional Additives Division, Specialty Solutions SBU
Asahi Kasei Corporation
E-mail: hananogel@om.asahi-kasei.co.jp
Related data
